Yield10 Bioscience

Yield10 Bioscience, Inc. operates as an agricultural bioscience company. It focuses on the development of technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. The company was founded by Anthony J. Sinskey, Simon F. Williams and Oliver P. Peoples in June 1992 and is headquartered in Woburn, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company was founded by Anthony J. Sinskey, Simon F. Williams, and Oliver P. Peoples in 1992 and is headquartered in Woburn, MA.

WOBURN, Mass., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference. The conference is being held on September 14-16, 2020 virtually.

Yield10 Bioscience Announces Participation at The H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

Archer-Daniels-Midland Company

Cadiz

Corteva Inc

4 Agriculture Operations Stocks Set to Dodge Near-Term Industry Challenges

WOBURN, Mass., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share.  In addition, Maxim Group LLC has exercised its over-allotment option to purchase 116,835 shares of common stock, at the public offering price less underwriting discounts. Gross proceeds before deducting underwriting discounts and commissions and other offering expenses are approximately $4.0 million, inclusive of the over-allotment. Concurrent with the public offering, investors affiliated with existing investor Jack W. Schuler purchased 396,450 shares of Yield10’s common stock pursuant to a securities purchase agreement at the same price per share as in the public offering, in a separate private placement transaction.  The gross proceeds from the private placement were approximately $1.7 million. All shares in the public offering and private placement were sold by Yield10.

Yield10 Bioscience Announces Closing of $4.0 Million Public Offering, Including Exercise of the Over-Allotment Option, and Concurrent $1.7 Million Private Placement

WOBURN, Mass., Aug.  22, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the pricing of its underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. The gross proceeds from the public offering will be approximately $3.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Yield10 also announced that investors affiliated with existing investor Jack W. Schuler, have agreed to purchase 396,450 shares of Yield10’s common stock pursuant to a securities purchase agreement with Yield10 at the same price per share as in the public offering, in a separate private placement transaction that is expected to close concurrently with the public offering.  The gross proceeds from the private placement will be approximately $1.7 million.  All shares in the public offering and private placement are to be sold by Yield10.

Yield10 Bioscience Announces Pricing of $5.2 Million Public Offering and Concurrent Private Placement

WOBURN, Mass., Aug.  21, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it has commenced an underwritten public offering of shares of its common stock. Yield10 also plans to enter into a separate securities purchase agreement with investors affiliated with existing investor Jack W. Schuler, pursuant to which the investors would agree to purchase shares of Yield10’s common stock, in a separate private placement transaction. The private placement would be at a price per share equal to the price per share in the proposed public offering and is expected to close concurrently with the public offering. The public offering is subject to market conditions and the private placement is contingent upon the closing of the public offering, and there can be no assurance as to whether or when the public offering and private placement may be completed, or the actual size or terms of the public offering and private placement.

Yield10 Bioscience Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

WOBURN, Mass., Aug.  17, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited trait C3007 in canola plant lines developed for increased oil content.  Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s  website .  

Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulated Status of its CRISPR Genome-Edited C3007 Trait in Canola; Plans U.S. Field Tests for 2021

Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2020 Results - Earnings Call Transcript

WOBURN, Mass., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and six months ended June 30, 2020.

Yield10 Bioscience Announces Second Quarter 2020 Financial Results

WOBURN, Mass. and GIBSON CITY, Ill., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has signed a three-year non-exclusive research agreement with GDM (“GDM”), a company specialized in plant genetics based in Gibson City, Illinois to evaluate novel yield traits in soybean.

Yield10 Bioscience Signs Research Agreement with GDM to Evaluate New Yield Traits in Soybean

WOBURN, Mass., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its second quarter 2020 financial results and provide a corporate update on Tuesday, August 11, 2020.

Yield10 Bioscience to Announce Second Quarter 2020 Financial Results and Host a Conference Call on Tuesday, August 11, 2020

WOBURN, Mass., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it established 50 acres of spring Camelina under contract with a grower in Montana in the second quarter of 2020. This is a business development activity necessary to gain experience in establishing the value chain for producing Camelina sativa seed at large scale as a source of new crop products. The objective of this activity was to gain experience in seed bulk-up, grower contracts, logistics and handling of harvested seed, including toll crushing, and to produce quantities of oil and protein meal for customer sampling. The crop has reached maturity and is currently drying down with harvesting expected in the weeks ahead.

Yield10 Bioscience Announces Spring Planting of 50 Acres of Wild-Type Spring Camelina to Support Business Development Plans

WOBURN, Mass., June  17, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced it has begun its 2020 Field Test Program based on the recent completion of planting at all sites contracted for the trials in the United States and Canada. Yield10’s 2020 Field Test Program is designed to evaluate several novel traits in Camelina and canola and the Company expects to harvest the plants and begin reporting data from the field tests in the fourth quarter of 2020.

Yield10 Bioscience Begins 2020 Field Test Program to Evaluate Novel Yield Traits in Camelina and Canola

Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q1 2020 Results - Earnings Call Transcript

WOBURN, Mass., May  14, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three months ended March 31, 2020.

Yield10 Bioscience Announces First Quarter 2020 Financial Results

WOBURN, Mass., May  14, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company has secured all of the regulatory permits required to conduct field tests for multiple traits at sites in the United States and Canada contracted for the 2020 growing season. Yield10’s 2020 Field Test Program will evaluate several novel traits in Camelina and canola. Planting is expected to begin in second quarter 2020 pending suitable weather conditions.

Yield10 Bioscience Secures Regulatory Permits for U.S. and Canadian Sites and Announces Plans for 2020 Field Test Program in Camelina and Canola

WOBURN, Mass., April  27, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited C3007 trait in Camelina sativa plant lines designed to increase oil content. Yield10’s submission along with the USDA-APHIS BRS response is posted on the  USDA’s website .

Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulatory Status of its CRISPR Genome-Edited C3007 Trait in Camelina, Paving the Way for U.S. Field Tests

Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q4 2019 Results - Earnings Call Transcript

-- 2019 Field Test Results Highlight CRISPR Technology Approach to Increase in Oil Content in Oilseed Crops

Yield10 Bioscience Announces Results of 2019 Field Test Program

WOBURN, Mass., March  10, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, announced today that it achieved key milestones in an early development program in corn to evaluate novel seed yield traits. Corn is the highest value commercial crop grown in the United States.

Yield10 Bioscience Achieves Key Milestones in Early Development Program in Corn to Evaluate Novel Traits

WOBURN, Mass., Feb.  13, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN today announced that Sherri M. Brown, Ph.D. was appointed to the Company’s Board of Directors effective February 11, 2020.  In connection with her appointment, Dr. Brown will serve as chair of a newly formed Science and Technology Committee of the Board. Dr. Brown previously served as a Special Commercial and Technical Advisor to the Company.

Yield10 Bioscience Appoints Agriculture Industry Veteran Sherri M. Brown, Ph.D.

WOBURN, Mass., Jan.  31, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today that it has received a letter from The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. The letter noted that as of January 30, 2020, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and Nasdaq considers the matter closed.

Yield10 Bioscience Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

WOBURN, Mass., Jan.  16, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has submitted an "Am I Regulated?" letter to USDA-APHIS's Biotechnology Regulatory Services (BRS) to confirm that the use of CRISPR genome-edited trait C3007 in Camelina sativa plant lines for increased oil content does not meet the definition of a regulated article under 7 CFR Part 340 regulations. Once regulatory status of the plants is confirmed, Yield10 plans to conduct field tests of CRISPR genome-edited Camelina plants in the United States.

Yield10 Bioscience Submits "Am I Regulated?" Letter to USDA-APHIS BRS for CRISPR Genome-Edited C3007 in Camelina to Pave the Way for U.S.

WOBURN, Mass., Jan.  15, 2020  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it will effect a 1-for-40 reverse stock split of its common stock, following stockholder approval of the reverse stock split at the Company's special stockholders meeting held on January 9, 2020. The 1-for-40 reverse stock split will be effective as of the close of business on Wednesday, January 15, 2020 and the Company's common stock will begin trading on a split-adjusted basis on Thursday, January 16, 2020. 

Yield10 Bioscience Announces 1-for-40 Reverse Stock Split

WOBURN, Mass., Nov.  19, 2019  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today the closing of an equity offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of $11.5 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience. Both existing investors, including 40.1% shareholder Jack W. Schuler, and new institutional investors participated in the offering.

Yield10 Bioscience Announces Closing of $11.5 Million Equity Offering and Full Exercise of Over-allotment Option

WOBURN, Mass., Nov.  15, 2019  (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today the pricing of a $10,750,000 equity offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of $10.75 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience.

News for Yield10 Bioscience Stock (YTEN)